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To develop consensus definitions for the core outcome set for pre-eclampsia. 73 
Study design 74 
Potential definitions for individual core outcomes were identified across four formal definition 75 
development initiatives, nine national and international guidelines, 12 Cochrane systematic 76 
reviews, and 79 randomised trials. Eighty-six definitions were entered into the consensus 77 
development meeting. Ten healthcare professionals and three researchers, including six 78 
participants who had experience of conducting research in low- and middle-income 79 
countries, participated in the consensus development process. 80 
Results 81 
Consensus definitions were developed for all core outcomes. When considering stroke, 82 
pulmonary oedema, acute kidney injury, raised liver enzymes, low platelets, birth weight, and 83 
neonatal seizures, consensus definitions were developed specifically for low- and middle-84 
income countries because of the limited availability of diagnostic interventions including 85 
computerised tomography, chest x-ray, laboratory tests, equipment, and 86 
electroencephalogram monitoring. 87 
Conclusions 88 
Consensus on measurements for the pre-eclampsia core outcome set will help to ensure 89 
consistency across future randomised trials and systematic reviews. Such standardization 90 
should make research evidence more accessible and facilitate the translation of research 91 
into clinical practice. 92 
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Randomised trials evaluating potential treatments for pre-eclampsia have reported many 101 
different outcomes.[1-3] Variation in outcome reportingexistss across many 102 
differenthealthcaree conditions, includingendometriosiss, selective fetal growth restriction, 103 
and neonatal car.[4-6] This variation exists because of a failure to take into account the 104 
perspectives of women when selecting outcomes, variations in outcome definitions, and the 105 
selective reporting of outcomes based onstatisticallsignificancee. Problems with poor 106 
outcome selection, measurement, and reporting can be addressed by developing, 107 
disseminating, and implementing core outcome sets.[7] 108 
 109 
A core outcome set for randomised trial evaluating treatments following the development of 110 
pre-eclampsia has been established to standardise outcome selection, collection, and 111 
reporting across future pre-eclampsia research (Figure 1). The core outcome set was 112 
developed in a three stage process using consensus science methods advocated by the 113 
Core Outcome Measures in Effectiveness Trials (COMET) Initiative.[8, 9] In summary, 114 
potential core outcomes were identified by developing an inventory of outcomes reported in 115 
pre-eclampsia trials and by undertaking a thematic analysis of interviews with women with 116 
lived experience of pre-eclampsia.[1, 10, 11] The long list of potential core outcomes was 117 
entered into a modified Delphi method which identified consensus outcomes. These 118 
outcomes were subsequently entered into a face-to-face consensus development meeting. 119 
Using a modified Nominal Group Technique, consensus outcomes were further prioritized to 120 
identify the final core outcome set (Table 1).[12] 121 
 122 
Different definitions exist for individual core outcomes. For example, stillbirth has previously 123 
been defined using six different combinations of gestational ages, birth weights, and crown-124 
heel heights.[13] Such variation makes it difficult to synthesise the results of individual trials 125 
within secondary research, including pairwise, individual patient data, and network meta-126 
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analysis.[14] Standardising definitions for individual core outcomes presents an opportunity 127 
to develop additional harmony in future pre-eclampsia research. 128 
 129 
In this study, we used formal consensus development methods to generate agreement on 130 
definitions for the core outcome set for pre-eclampsia. 131 
 132 
Methods 133 
An international steering group, including health care professionals, researchers, and 134 
women with lived experience of pre-eclampsia, was established to provide a perspective to 135 
inform key methodological decisions and to approve the final core outcome set. The protocol 136 
and other methodological decisions were informed by COMET initiative recommendations, a 137 
systematic review of registered, ongoing, and completed core outcome sets, and the 138 
steering group’s experience of developing core outcome sets in other areas. [8, 9, 12, 15-26] 139 
 140 
Potential definitions were sourced from formal definition development initiatives, national and 141 
international guidelines, Cochrane reviews, and randomised trials (Figure 2). Specific 142 
methods have been published elsewhere [8], briefly: 143 
 A systematic review was undertaken searching the Core Outcome Measures in 144 
Effectiveness Trials initiative register to identify definition development initiatives relevant 145 
to pregnancy and childbirth research from inception to January 2017.[12]  146 
 A systematic review of national and international pre-eclampsia guidelines was used to 147 
source definitions used within these guidelines.[27]  148 
 Cochrane systematic reviews evaluating potential treatments for pre-eclampsia were 149 
identified by searching the Cochrane Database of Systematic Reviews from inception to 150 
August 2017, again aiming to identify standardised definitions. 151 
 Randomised trials evaluating potential treatments for pre-eclampsia where outcomes 152 
may have been defined were identified by searching bibliographical databases, including 153 
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the Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE, from 154 
inception to January 2016.[1] 155 
From these different sources, an inventory of potential definitions was developed.[28] 156 
 157 
A face-to-face consensus meeting is recommended by the COMET initiative and has been 158 
used by other core outcome set developers.[9] The setting in which the face-to-face 159 
consensus meeting takes is known to affect the interaction of participants, and can ultimately 160 
impact the quality of the decision making.[29] Outside the context of core outcome set 161 
development, there is limited experience of delivering formal consensus methods using 162 
teleconferencing formats which would overcome resource limitations and geographical 163 
barriers. Following careful consideration, a face-to-face consensus meeting was considered 164 
the optimal approach.  165 
 166 
Healthcare professionals and researchers who had participated in the Delphi survey were 167 
invited to participate in a face-to-face consensus development meeting.[8] Resource 168 
limitations prevented the reimbursement of international travel and subsistence expenses 169 
and participation was limited to the United Kingdom. There is no robust method for 170 
calculating the required number of participants.[29] Following consultation with the study’s 171 
steering group, we aimed to recruit between ten and 15 participants.  172 
 173 
Before the meeting, participants provided demographic details. The consensus development 174 
meeting was moderated by an experienced and trained facilitator, Prof. Richard McManus. 175 
Each core outcome was discussed in turn. Potential definitions were displayed within the 176 
definition hierarchy. Participants were encouraged to voice their opinions on previously used 177 
definitions, to suggest new definitions if necessary, and to reformulate individual definitions 178 
to improve clarity or comprehension. Although the group was encouraged to reach 179 
consensus, members were able to express minority or alternative views when consensus 180 
could not be achieved.  181 




The study’s steering group approved the final consensus definitions. They were also able to 183 
provide feedback to improve clarity. 184 
 185 
This study is complementary to the work of the International Society for the Study of 186 
Hypertension in Pregnancy (ISSHP) and the Global Pregnancy Collaboration who are 187 
engaged with the standardisation of study design, the development of a standardised 188 
database for perinatal research studies, and the development of clinical practice guidelines. 189 
[30, 31] 190 
 191 
Results 192 
Eighty-six potential outcome definitions were drawn from four definition development 193 
initiatives (Appendix S1), nine national and international clinical practice guidelines, 12 194 
Cochrane systematic reviews, and 79 pre-eclampsia trials [1]. Thirteen participants 195 
participated in the consensus development meeting (Table 2) comprising ten healthcare 196 
professionals and three researchers. Six had experience of working in or conducting 197 
research in low- and middle-income countries. 198 
 199 
Participants agreed maternal core outcomes should be collected up to 42 days following 200 
delivery. Offspring core outcomes should be collected for the first 28 days of life. If a baby is 201 
born prematurely, outcomes should be collected up to 28 days beyond the estimated due 202 
date. 203 
 204 
Maternal core outcomes 205 
Maternal mortality: Participants noted consistency across definitions in terms of a limit of 42 206 
days after delivery, inclusion of pregnancy termination or miscarriage, and a historical limit 207 
based upon the approximate timing of first menstrual period in non-lactating women.[32] 208 
Participants discussed the possibility of extending the definition by including deaths 209 
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attributable to complications of pre-eclampsia later than 42 days; however, concerns were 210 
expressed regarding the feasibility of undertaking longer follow-up in low- and middle- 211 
income countries (Table 3). 212 
 213 
Eclampsia: Participants identified inconsistencies in terminology across different definitions 214 
of eclampsia. A unanimous decision was made to define eclampsia as “the onset of 215 
convulsions in a woman with pre-eclampsia not attributable to other causes”. Participants 216 
discussed the importance of acknowledging the various terminology used in different 217 
settings related to convulsions including fits, generalised convulsions, tonic-clonic seizure, 218 
and seizure. 219 
 220 
Stroke: Participants recognised pre-eclampsia as an important risk factor for both ischemic 221 
and hemorrhagic stroke.[33] Discussion focused upon the challenges of obtaining 222 
computerised tomography or magnetic resonance imaging in low- and middle-income 223 
countries, and as such separate definitions were agreed for high-income countries and low- 224 
and middle-income countries. 225 
 226 
Cortical blindness: In the single potential definition identified, participants noted the 227 
requirement to measure visual acuity and the challenges of doing so. Such measurement is 228 
not a core competency for healthcare professionals in maternity settings, and the necessary 229 
equipment to measure visual acuity is often not readily available. Participants concluded a 230 
patient-reported symptom of visual impairment would be comparable and negate the 231 
requirement to undertake visual acuity measurement.  232 
 233 
Retinal detachment: Participants appreciated the simplicity of the World Health 234 
Organization’s definition: “a condition in which the retina peels away from its underlying layer 235 
of support tissue.”[34] However, the importance of undertaking an ophthalmological 236 
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examination to confirm the diagnosis was discussed and considered essential in securing a 237 
robust diagnosis. 238 
 239 
Pulmonary oedema: Participants agreed the clinical signs of pulmonary oedema are 240 
relatively straightforward to elicit during respiratory system auscultation. The discussion 241 
focused upon chest x-ray confirmation, with concerns expressed regarding the availability of 242 
X-ray facilities in low- and middle-income countries. Participants therefore agreed to include 243 
the requirement for an oxygen saturation below 95% and diuretic treatment when a chest x-244 
ray is unavailable. 245 
 246 
Acute kidney injury: Participants noted a diverse range of different definitions of acute kidney 247 
injury. A pragmatic decision was made to implement the National Institute for Health and 248 
Care Excellence standardised definition which shares a common definition with other recent 249 
national and international initiatives, including Risk, Injury, Failure, Loss, End-stage (RIFLE) 250 
renal disease, Acute Kidney Injury Network, and Kidney Disease: Improving Global 251 
Outcomes. [35-38] The discussion focused upon the measurement of creatinine during 252 
routine antenatal care. A baseline creatinine is not routinely measured in lower risk women 253 
and may not have been measured before pregnancy.[39] Therefore, an additional criterion 254 
was added to the consensus definition: serum creatinine >150 µmol/L (> 1.6 mg/dl) in the 255 
absence of a baseline serum creatinine. A lower threshold was thought not to be sufficiently 256 
discriminatory in the absence of a baseline measurement. It was noted that the inclusion of 257 
oliguria within the definition would assist with securing the relevance of the definition within 258 
low- and middle-income countries where the measurement of serum creatinine was not 259 
consistently available. 260 
 261 
Liver capsule haematoma: Participants unanimously recommended the definition previously 262 
reported in randomised trials adopted from the prediction of adverse maternal outcomes in 263 
pre-eclampsia study.[40] 264 




Placental abruption: Participants unanimously agreed the definition developed as part of the 266 
Brighton Collaboration case definition study.[41] 267 
 268 
Postpartum haemorrhage: Participants discussed the challenges of defining postpartum 269 
haemorrhage when considering the contribution of the mode of delivery, estimating blood 270 
loss, and differences in thresholds when further medical or surgical intervention to manage 271 
postpartum haemorrhage is deemed necessary. Participants agreed a common starting 272 
point is the recognition of heavy abnormal bleeding following childbirth. A specific volume 273 
threshold was considered unhelpful as there is marked inter-observer variability in estimating 274 
blood loss.[42] Participants discussed the importance of demonstrating hypotension and/or 275 
the use of pharmacologic or surgical interventions to manage postpartum haemorrhage as 276 
important components of the consensus definition. 277 
 278 
Raised liver enzymes: Participants recognised that the reference ranges for liver 279 
transaminases vary both during the three trimesters of pregnancy and between different 280 
laboratories. Participants unanimously recommended the consensus definition should not 281 
state a specific threshold but that aspartate aminotransferase (AST) and alanine 282 
transaminase (ALT) should be elevated at least twice the upper limit of normal for the 283 
laboratory where the sample is tested. Participants noted the measurement of liver enzymes 284 
might not be available in all settings in low- and middle-income countries.  285 
 286 
Low platelets: Participants discussed the different thresholds defining thrombocytopenia. In 287 
pregnancy thrombocytopenia is defined as a platelet count of less than 150 x 109/L; 288 
however, counts below 100 x109/L are more typical in HELLP syndrome and in severe 289 
cases, the platelet count may fall below 30 x109/L.[43, 44] Participants agreed that platelet 290 
counts below 100 x109/L should be used as the threshold for the consensus definition. 291 
 292 
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Admission to intensive care unit required: Participants unanimously agreed on a consensus 293 
definition, highlighting the importance of collecting and reporting the requirement for 294 
intensive care unit admission even if women are unable to be admitted to an intensive care 295 
unit because of logistics or availability of such services. The lack of unit capacity will be 296 
particularly relevant to research conducted in low- and middle-income countries.[45] 297 
 298 
Intubation and mechanical ventilation not for purposes of operative delivery: Participants 299 
unanimously agreed on a consensus definition. 300 
 301 
Offspring core outcomes 302 
Stillbirth: Participants reviewed the different definitions which incorporated different 303 
quantifiable parameters, including clinical estimates of gestational age, birth weight, and 304 
crown-heel height.[46] Participants highlighted the World Health Organization’s definition for 305 
stillbirth is the most widely used.[47] The inclusion of height and weight thresholds secures 306 
its feasibility in low- and middle-income countries.[47] Consensus was reached to select the 307 
World Health Organization’s definition.[34] 308 
 309 
Gestational age at delivery: Participants considered gestational age at delivery as a well-310 
characterised outcome with an internationally accepted definition.[48] There was unanimous 311 
agreement to adopt this definition. 312 
 313 
Birth weight: Participants agreed birth weight should be collected within 24 hours of birth.[48] 314 
Participants noted best practice recommendations regarding the measurement of birth 315 
weight should be adhered to in future pre-eclampsia research including weight assessed 316 
using a calibrated electronic scale with 10-gram resolution.[48] Participants noted that in low- 317 
and middle-income countries calibrated electronic scales may not be readily available, and 318 
the calibration and type of scale should be clearly reported. Participants recommended birth 319 
weight should be reported separately for each infant in a mutli-fetal pregnancy. 320 




Small for gestational age infants: Participants discussed the importance of assessing small 322 
for gestational age using validated growth charts. A variety of different international, regional, 323 
and local growth charts are available.[49] Participants unanimously agreed a 10th percentile 324 
threshold was appropriate to identify small for gestational age newborn infants and any 325 
validated international, regional, or local customised growth chart could be used. 326 
Researchers should clearly report the customised growth chart they used. Participants 327 
agreed small for gestational age infants should be reported for all births, including stillbirths. 328 
 329 
Neonatal mortality: Participants noted the consistent use of the World Health Organization 330 
definition for neonatal mortality, “deaths among live births during the first 28 completed days 331 
of life”, across definition development initiatives, international and national guidelines, 332 
Cochrane systematic reviews, and randomised controlled trials.[34] When considering 333 
preterm infants, neonatal mortality should be reported if death occurs within 28 days of the 334 
estimated due date. 335 
 336 
Neonatal seizures: Participants noted World Health Organization guidelines described the 337 
most practical method of diagnosing neonatal seizures, based upon clinical recognition.[50] 338 
Neonatal seizures commonly present with focal clonic movements; however, they can 339 
present with more subtle signs which can be easily misinterpreted as either crying or cycling 340 
movements of the limbs.[50] Electroencephalogram (EEG) monitoring can support the 341 
diagnosis. However, its availability in low- and middle-income countries is limited. 342 
Participants agreed a common starting point is the recognition of neonatal seizures. 343 
Separate definitions were agreed for high-income countries and low- and middle-income 344 
countries.  345 
  346 
Respiratory support: Participants agreed on a consensus definition which included 347 
continuous positive airway pressure, non-invasive positive pressure ventilation, or intubation 348 
Standardising definitions for pre-eclampsia research 
13 
 
and mechanical ventilation. When considering low- and middle- income countries 349 
specifically, headbox oxygen and nasal cannula oxygen would be included within the 350 
definition. Participants discussed the inclusion of supplemental oxygen; however, concerns 351 
were expressed that this would represent an overly inclusive definition as supplemental 352 
oxygen is a commonly used non-specific intervention.[51] 353 
 354 
Admission to a neonatal unit required: Participants discussed the lack of consensus 355 
regarding the local, regional, or national criteria used to assess the need for admission to a 356 
special care baby unit or neonatal intensive care unit.[52] Consensus was reached to 357 
recommend a broad definition to recognise this variation in admission criteria. The definition 358 
highlights the importance of collecting and reporting the requirement for admission to a 359 
special care baby unit or neonatal intensive care unit even if the neonate cannot be 360 
admitted. The lack of capacity will be particularly relevant to research conducted in low- and 361 
middle-income countries.[53] 362 
 363 
Disucssion 364 
Using formal consensus methods, healthcare professionals and researchers have developed 365 
standardised definitions for the core outcome set for pre-eclampsia. For stroke, pulmonary 366 
oedema, acute kidney injury, raised liver enzymes, low platelets, birth weight, and neonatal 367 
seizures, consensus definitions were developed specifically for low- and middle-income 368 
countries because of the limited availability of diagnostic interventions including chest x-ray, 369 
laboratory tests, and equipment (Table 3). Such modification ensures the core outcome set 370 
can be feasibly collected in low- and middle-income countries. The consensus definition for 371 
maternal admission to intensive care and admission to a neonatal unit emphasised the 372 
requirement for admission, to address potential lack capacity which can occur in all settings. 373 
 374 
This study has completed our overall objective of producing a core outcome set aiming to 375 
standardise future pre-eclampsia trials and systematic reviews by identifying what outcomes 376 
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to measure, when they should be measured, and how they should be measured. A 377 
comprehensive inventory of potential definitions was developed by a diverse range of 378 
researchers and healthcare professionals resulting in clear definitions which could be used 379 
to collect core outcomes across different settings. 380 
 381 
This study is not without limitations. Participants in the consensus meeting currently live in 382 
the United Kingdom, although six participants (46%) had lived, worked, or conducted 383 
research in a low- and middle-income country. This could have impacted on the 384 
generalisability of the consensus definitions prioritised but was a pragmatic choice in the 385 
light of limited resources which precluded inclusion of international participants. Use of the 386 
core outcome set in a variety of countries will ascertain the extent to which this is an issue 387 
and definitions may need further adjustment. 388 
 389 
The consensus development meeting did not include women with lived experience of pre-390 
eclampsia because the anticipated discussion would involve the technical details of outcome 391 
definition and collection. Once a consensus definition was formally agreed, participants had 392 
the opportunity to comment further. The study design could have incorporated formal and 393 
anonymous voting to assess the level of agreement for individual consensus definitions. 394 
Further methodological research is required to develop an appropriate definition of 395 
consensus in exercises similar to ours. 396 
 397 
Having established consensus definitions, researchers should use them, and guideline 398 
developers should build their clinical practice guidelines around them. However, consensus 399 
definitions are not meant to prevent the use of other appropriate definitions in specific 400 
circumstances. For example, researchers undertaking research in Australia may wish to 401 
define stillbirth as occurring after 20 weeks of gestation in line with local Epidemiology and 402 
Surveillance Branch recommendations.[13] Researchers wishing to collect data using other 403 
definitions in the context of their own randomised trial would continue to be able to do so. 404 
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However, selective reporting should be avoided by presenting findings for both the 405 
consensus definition and any other definition used. The consensus definitions should always 406 
be the primary definition collected and reported. Researchers would need to carefully 407 
consider how these data would be collected to fulfil different definitions. In the example of a 408 
stillbirth, the common components of all definitions, including gestational age, birth weight, 409 
and crown-heel height, should be recorded separately and combined to fulfil the consensus 410 
definition (gestational age, birth weight, and crown-heel height) and the Australian definition 411 
(gestational age and birth weight). 412 
 413 
Consensus definitions should prevent misclassifications and reduce measurement error.[54] 414 
Such standardisation ensures the consensus definitions can be applied symmetrically to the 415 
trial arms, avoiding bias in the measurements. Several consensus definitions, including 416 
abruption, postpartum haemorrhage, and neonatal seizures, require professional 417 
assessment. Any assessment should be determined by an observer with comprehensive 418 
training. Differential and biased misclassification of outcomes can occur in poorly designed 419 
randomised trials. For example, for postpartum haemorrhage: outcome assessors may 420 
perform laboratory investigations more regularly in participants allocated to the experimental 421 
treatment when compared to the control. Systematic evaluations of observer bias have 422 
demonstrated non-masked outcome assessors consistently over diagnose clinical outcomes 423 
when compared with masked outcome assessors.[55] Several strategies exist to increase 424 
the likelihood of standardised definitions being applied to accurately classify clinical 425 
outcomes, including standardised data collection tools, validation studies, and independent 426 
adjudication panels. This would increase the likelihood that core outcomes are classified 427 
accurately and without variation.[56] 428 
 429 
The Core Outcomes in Women’s and Newborn Health (CROWN) initiative, supported by 430 
over 80 specialty journals, including Pregnancy Hypertension: An International Journal of 431 
Women's Cardiovascular Health, have resolved to implement the core outcome set for pre-432 
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eclampsia.[12] Participating journals will require researchers to report the definition for 433 
individual core outcomes within randomised trial and systematic review reports. When the 434 
consensus definition has not been used, the researchers will be asked to report their 435 
definition. 436 
 437 
Successful implementation should help to enable the coordination and planning of pre-438 
eclampsia research within a regional, national, and international context.[57] Other 439 
initiatives, including the development of research prioritiess, standardising the definition of 440 
hypertension disorders in pregnancy, and standardised data collection tools could support 441 
national and international co-operatio.[58] Ensuring core outcomes are consistently defined 442 
across future randomised controlled trials and systematic reviews, will secure evidence 443 
which is more accessible and facilitate the translation of research into clinical practice.[59, 444 
60] It is hoped the core outcome set will ultimately improve the outcomes of women and their 445 
babies. 446 
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